WO2014168522A9 - Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения - Google Patents
Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения Download PDFInfo
- Publication number
- WO2014168522A9 WO2014168522A9 PCT/RU2014/000264 RU2014000264W WO2014168522A9 WO 2014168522 A9 WO2014168522 A9 WO 2014168522A9 RU 2014000264 W RU2014000264 W RU 2014000264W WO 2014168522 A9 WO2014168522 A9 WO 2014168522A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydrogen
- heterocyclic group
- group containing
- isa
- Prior art date
Links
- 0 CC(*)NC(C(C)(*)C(C)(*)C(*)(*)C(O)=O)OC Chemical compound CC(*)NC(C(C)(*)C(C)(*)C(*)(*)C(O)=O)OC 0.000 description 2
- XSCWNIYWUQJYHG-UHFFFAOYSA-N N[U](Cc1c[nH]c2c1cccc2)#[N][U] Chemical compound N[U](Cc1c[nH]c2c1cccc2)#[N][U] XSCWNIYWUQJYHG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
- C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Definitions
- the invention relates to new biologically active compounds - derivatives of glutarimides or their pharmaceutically acceptable salts, their use as agents for the prevention and treatment of diseases of the upper respiratory tract, as well as to methods for producing the proposed compounds.
- Chronic diseases of the upper respiratory tract are among the most common diseases in children and adults around the world.
- Chronic diseases of the upper respiratory tract include, in particular, rhinosinusitis.
- Rhinosinusitis is an inflammation of the mucous membrane of the nasal cavity and paranasal sinuses (SNP), the problem of which is currently one of the most urgent in otorhinolaryngology (Fokkens WJ, Lund VJ, Mullol J. et al., European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinology 2007; 45; 20: 1-139).
- Acute rhinosinusitis is a common complication in acute respiratory viral infection (ARVI).
- corticosteroids are used as monotherapy or in combination with antibiotics. In the case of more severe forms of rhinusinusitis, antibiotics are used.
- the main corticosteroids are fluticasone, budesonide and mometasone.
- Corticosteroids in the treatment of rhinusinusitis are prescribed for long courses, which can cause side effects and tolerance. Side effects, as a rule, are a manifestation of the actual glucocorticoid action of these drugs, but to a degree exceeding the physiological norm.
- Antibiotics are usually prescribed penicillin group antibiotics (amoxicycline, penicillin V) or non-penicillin antibiotics (macrolides, tetracyclines) (Fokkens WJ, Lund VJ, Mullol J. et al., European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinology 2007 ; 45; 20: 1-139).
- the aim of the present invention is the development and introduction of new drugs for the treatment of rhinusinusitis.
- classes IV and V include viruses containing single-stranded (+) or (-) RNA.
- Class IV includes representatives of the genus enteroviruses from the picornavirus family and the coronavirus family
- class V includes the respiratory syncytial virus (RSV) of the paramyxovirus family and the influenza virus of the orthomyxovirus family.
- RSV respiratory syncytial virus
- Rhinoviruses are responsible for at least 80% of catarrhal diseases.
- rhinovirus inf infections cause a large number of complications, such as sinusitis and inflammation of the middle ear, and are often detected by virological examination of children with pneumonia.
- rhinovirus infection causes exacerbation in 80% of cases.
- rhinoviruses can cause exacerbation of asthma as well and chronic obstructive pulmonary disease, chronic bronchitis, cystic fibrosis, rhinoviruses were isolated in patients with pneumonia in immunodeficiency states.
- Coxivirus infection is a large group of diseases characterized by severe clinical polymorphism.
- the manifestation of coxivirus infection can be expressed by meningitis, paralysis, acute respiratory disorders, pneumonia, hemorrhagic conjunctivitis, myocarditis, hepatitis, diabetes and other syndromes.
- viruses - human enteroviruses in the genus Enterovirus are divided into five types: 1) poliovirus; 2) human enterovirus A; 3) human enterovirus B; 4) human enterovirus C; 5) human enterovirus D.
- enterovirus A human enterovirus A2-8, 10, 12, 14, 16
- human enterovirus B human enterovirus B
- human enterovirus C Human enterovirus C (Coxsackie A1, 1 1, 13, 15, 17-22, 24).
- Coxsackie viruses like other human enteroviruses, are ubiquitous throughout the world. Temperate countries are characterized by a maximum of their circulation in the summer-autumn season. Viruses have a high degree of invasiveness, which leads to their rapid spread in the human population. Koksaki viruses are often the cause of a “sudden” outbreak in organized children's groups, hospitals, and there is also an intrafamily spread of the infection. An important role in the epidemiology of coxsivirus and other enterovirus infections in humans is played by the high level of variability of the viral genome. The consequence of this is the ability of certain serotypes to cause various pathologies in certain circumstances.
- the same clinical syndrome may be due to different serotypes and different types of enteroviruses.
- enteroviruses As a result of genetic variability, selection and the rapid spread of altered viruses, large outbreaks of diseases arise, in the etiology of which these viruses did not previously participate, or their circulation was not observed for a long time.
- the primary reproduction of the Coxsackie virus occurs in the lymphoid tissue of the nasopharynx and intestines. It causes local lesions, expressed by symptoms of acute respiratory infections, herpangins, pharyngitis, etc. The virus is detected in the throat for up to 7 days, and with feces it is excreted 3-4 weeks (with immunodeficiencies - several years). Following the primary reproduction, the stage of viremia occurs, as a result of which the pathogen penetrates the target organs.
- Coxsackie viruses these can be the brain and back, brain, pia mater, upper respiratory tract, lungs, heart, liver, skin, etc.
- Coxsackie B viruses can cause severe generalized pathological processes in newborns.
- Viruses cause the development of the following clinical syndromes: serous meningitis (Koksaki A2, 3, 4, 6, 7, 9, 10, Koksaki B 1-6); acute systemic disease in children with myocarditis and meningoencephalitis (Coxsackie B l -5); paralysis (Koksaki Al, 2, 5, 7, 8, 9, 21, Koksaki B2-5); Herpangin (Koksaki A2, 3, 4, 5, 6, 8, 10); acute pharyngitis (Koksaki A10, 21); contagious runny nose (Koksaki A21, 24); damage to the upper respiratory tract and pneumonia (Koksaki A9, 16, Koksaki B2-5) (16); pericarditis, myocarditis (Koksaki B1-5); hepatitis (Koksaki A4, 9, 20, Koksaki B5); diarrhea of newborns and young children (Koksaki A 18,
- the Paramyxovirus family includes representatives of the genus respiviruses (human parainfluenza virus types 1, 2, 3, 4 and 5) and pneumoviruses (respiratory syncytial virus).
- RSV Respiratory syncytial virus
- RSV is an important pathogen in newborns and young children and is responsible for ⁇ 70% of severe viral bronchiolitis and / or pneumonia, most of which are characterized by wheezing and shortness of breath. These bronchiolitis are the most common cause of hospitalization in the winter season during the first year of a child's life. RSV also causes bronchiolitis, pneumonia, and chronic obstructive pulmonary disease in people of all ages and contributes significantly to excess mortality in the winter season.
- RSV is the main inducer of wheezing and asthma complications.
- Adult patients infected with RSV have an increased risk of developing asthma complications leading to hospitalization than healthy patients (Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005; 352 (17): 1749-1759).
- PCB is a leader in the number of deaths among viral infections. In the United States alone, more than $ 2.4 billion is spent on the treatment of viral diseases of the lower respiratory tract in children. By the first year of life, 50-65% of children become infected with this virus, and by the age of two almost 100% of children become infected. To the high-risk group, in addition to premature newborns and the elderly, people who have diseases of the cardiovascular, respiratory and immune systems belong.
- Adaptive immunity resulting from RSV infection in both children (with an immature immune system) and adults is short-term and does not provide complete antiviral protection. This fact leads to the appearance of reinfection observed throughout life. In the blood of newborns in the first months of life, they contain maternal anti-RSV antibodies, but they do not protect the child.
- ribavirin is a relatively toxic agent that often causes anemia. Its main feature is prolonged deposition in red blood cells. As a result, traces of ribavirin are detected even 6 months after the end of the course of therapy. The teratogenic effect of ribavirin is also mentioned.
- Influenza virus belongs to the family of orthomyxoviruses, which includes four genera: influenza A, B and C viruses and togoviruses (sometimes called influenza D virus).
- influenza A, B, and C viruses and togoviruses (sometimes called influenza D virus).
- a person can become infected with the influenza A, B, and C virus types, but only type A viruses cause pandemics that pose a serious threat to humans.
- WHO the flu causes 3-5 million cases of serious illness every year and from 250,000 to 500,000 deaths worldwide.
- Influenza virus is also released in patients with exacerbation of asthma, however, the number of cases is 1-9% of the number of other viruses.
- Type A viruses are divided into subtypes based on various combinations of sixteen hemagglutinin variants and nine neuraminidase variants. All known subtypes have been confirmed for wild birds, which are considered a natural host for influenza A viruses. Only three subtypes, namely A (H1N1), A (H2N2) and A (H3N2), are known in the human population. These viruses, together with influenza B viruses, are responsible for the annual epidemics of varying severity. A variety of influenza viruses is a genetically determined trait.
- RNA gene segmented with the negative polarity of the influenza virus promotes the exchange of genomic segments (the so-called reassortment) between different strains in the process of mixed infection.
- the lack of corrective activity in influenza polymerase leads to a high mutation rate of viral genes.
- flu strains with “new” antigenic properties regularly appear. If the change is sufficient to overcome the existing immunity in the population, the virus can cause epidemics. In the case when the human population is completely immune to the emerging variant, the virus can easily infect and spread from infected to uninfected people and cause a pandemic.
- Adamantane derivatives (amantadine and rimantadine) act against influenza A (but not B).
- Drugs that inhibit neuraminidase are zanamivir and oseltamivir. Both types of drugs act primarily in the early stages of infection.
- the most common method for the synthesis of imides of dicarboxylic acids is the method of thermal cyclization, which consists in heating a dicarboxylic acid or its derivative, such as anhydride, diester, etc. with a primary amine or its amide.
- the yield of cyclic imides is usually 80%, however, since the process is carried out at high temperatures, it can only be used for the synthesis of thermally stable imides [Weigand - Hilgetag. Experimental methods in organic chemistry. Ed. prof. N. N. Suvorova. M, Chemistry, 1968, p. 446].
- this article provides a synthesis scheme for glutarimidotryptamine and succinimidotryptamine based on tryptamine and anhydrides of the corresponding acids when boiled in acetic acid. Glutarimidotryptamine is obtained by this method with a yield of 67%, succinimidotryptamine 81%.
- the publication of international application WO 2007/007054 discloses derivatives of succinimides and glutarimides of the general formula (I) having an action that inhibits DNA methylation in cells, in particular in tumor cells.
- Compounds disclosed in this publication are prepared by reacting a combination of an amino derivative containing a hydrocarbon chain with the corresponding anhydride or acid or ether, followed by, if necessary, closing the ring, optionally in the presence of a base.
- the present invention relates to glutarimide derivatives of the general formula I:
- n is an integer from 0 to 2;
- R a i, R b i, R c i, R d i, R e i, R f i each independently represents hydrogen, Ci-C 6 alkyl; -NH 2 , -NHCi-C 6 alkyl, hydroxy, Ci-C 6 alkoxy;
- R 2 represents hydrogen, Ci-C 6 alkyl, a group —C (0) OH, —C (0) OC] —C 6 alkyl;
- R 3 represents:
- the compound is not a compound in which:
- R a i, R b i, R c i, R d i, R e i, R f i are hydrogen
- R 2 is —C (0) OCH 3
- R 3 is not:
- R a i, R b i, R C b R d i, R e i, R f ⁇ are hydrogen
- R 2 is hydrogen
- R 3 is not:
- R d i, R e i, R f i represent hydrogen
- R 2 represents hydrogen
- R 3 is not:
- the present invention also relates to a drug for the treatment of diseases of the upper respiratory tract, which is a derivative of glutarimides of the general formula (I) or their pharmaceutically acceptable salts.
- Another object of the present invention is a pharmaceutical composition for the treatment of diseases of the upper respiratory tract, comprising an effective amount of glutarimide derivatives of the general formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
- the present invention also relates to a method for treating diseases of the upper respiratory tract, comprising administering to the patient an effective amount of a glutarimide derivative of the general formula (I) or a pharmaceutically acceptable salt thereof.
- the present invention further relates to a method for producing glutarimide derivatives of the general formula I or their pharmaceutically acceptable salts by heating the dicarboxylic acid monoamide of the general formula II
- n is an integer from 0 to 2;
- R a i, R b i, R c i, R d i, R e i, R f i each independently represents hydrogen, Ci-C 6 alkyl; -NH 2 , -NHC) -C 6 alkyl, hydroxy, Ci-C 6 alkoxy;
- R 2 represents hydrogen Ci-C 6 alkyl, a group -C (0) OH, -C (0) OCi-C 6 alkyl;
- R 3 represents:
- Preferred compounds of the present invention are compounds of General formula I, where
- n is an integer from 0 to 2;
- R a i, R b i represents hydrogen, methyl, amino, hydroxy
- R ° i, R d i represents hydrogen, methyl, amino, hydroxy
- R e i, R f i represents hydrogen, methyl
- R 2 represents hydrogen, methyl, carboxyl group, methoxycarbonyl, ethoxycarbonyl
- R 3 represents:
- the most preferred compounds of the present invention are the compounds shown in table 1.
- additive salts of organic acids e.g., formate, acetate, maleate, tartrate, methanesulfonate, benzenesulfonate, toluenesulfonate, etc.
- additive salts of inorganic acids e.g., hydrochloride, hydrobromide, sulfate, phosphate, etc.
- salts with amino acids for example, aspartic acid salt, glutamic acid salt, etc.
- the most preferred known compounds that can be used in the pharmaceutical composition and method of treatment of the present invention are the glutarimide derivatives shown in table 2.
- the compounds of the present invention can be prepared by a process comprising heating the starting dicarboxylic acid monoamides of general formula II with a water-removing agent in an organic solvent medium or in the medium of the water-removing agent itself, optionally with the addition of sodium acetate.
- the heating is carried out at a temperature of from 90 ° C to 120 ° C, most preferably at 100 ° C, even more preferably boiling.
- Dicarboxylic acid anhydrides, organic acid chlorides and carbonyldiimidazole can be used as water-taking agents in this method.
- Preferred dewatering agents that can be used in the process are glutaric anhydride, propionic anhydride, acetic anhydride, acetic acid chloride and carbonyldiimidazole.
- propionic anhydride in toluene, glutaric anhydride, preferably in dimethylformamide, are used, or acetic anhydride in dioxane, or acetic acid chloride in acetic acid.
- the most preferred variant of the method is a method using acetic anhydride as a water-removing agent and solvent and heating at a temperature of 90-100 ° C.
- Glutarimide derivatives of the general formula I have a therapeutic effect on diseases of the upper respiratory tract.
- the compounds of the present invention can be used to treat diseases of the upper respiratory tract of a bacterial, viral, viral-bacterial etiology or caused by other other factors.
- diseases are rhinosinusitis, diseases caused by RNA viruses, such as rhinovirus, Coxsackie virus, respiratory syncytial virus and influenza virus, for example, exacerbation of asthma, chronic obstructive pulmonary disease, bronchitis and cystic fibrosis caused by rhinovirus, influenza virus and / or respiratory syncytial virus.
- the compounds of the present invention are administered in an effective amount that provides the desired therapeutic result.
- the compounds of general formula (I) can be administered orally, topically, parenterally, intranasally and inhaled in the form of unit dosage forms containing non-toxic pharmaceutically acceptable carriers.
- parenteral administration means subcutaneous, intravenous, intramuscular or intrathoracic injection or infusion.
- the compounds of the present invention can be administered to a patient in doses of 0.1 to 100 mg / kg body weight per day, preferably in doses of 0.25 to 25 mg / kg one or more times per day.
- the specific dose for each particular patient will depend on many factors, including the activity of the compound used, age, body weight, gender, general health status and diet of the patient, time and method of administering the drug, speed of its removal from an organism, the combination of drugs used specifically, and the severity of the disease in the individual being treated.
- compositions of the present invention contain a compound of general formula (I) in an amount effective to achieve the desired result, and can be administered in unit dosage forms (e.g., in solid, semi-solid or liquid forms) containing the compounds of the present invention as an active ingredient in a mixture with a carrier or excipient suitable for intramuscular, intravenous, oral, sublingual, inhaled intranasal administration.
- the active ingredient may be included in the composition along with commonly used non-toxic pharmaceutically acceptable carriers suitable for the manufacture of solutions, tablets, pills, capsules, dragees, emulsions, suspensions, ointments, gels and any other dosage forms.
- binders can be used.
- saccharides for example glucose, lactose or sucrose, mannitol or sorbitol, cellulose derivatives and / or calcium phosphates, for example tricalcium phosphate or calcium acid phosphate
- binders can be used.
- starch paste for example, corn, wheat, rice, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose and / or polyvinylpyrrolidone.
- disintegrating agents such as the aforementioned starches and carboxymethyl starch, cross-linked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate.
- Optional additives such as flow control agents and lubricants such as silica, talc, stearic acid and its salts such as magnesium stearate or calcium stearate, and / or propylene glycol can be used.
- the core of the dragee is usually coated with a layer that is resistant to the action of gastric juice.
- concentrated saccharide solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrrolidone, polyethylene glycol and / or titanium dioxide, and suitable organic solvents or mixtures thereof.
- additives As additives, stabilizers, thickeners, colorants and perfumes can also be used.
- hydrocarbon ointment bases such as white and yellow petroleum jelly (Vaselinum album, Vaselinum flavum), liquid paraffin (Oleum Vaselini), white and liquid ointment (Unguentum album, Unguentum flavum), and as additives to give more dense consistency, such as paraffin wax and wax; absorbent ointment bases such as hydrophilic petrolatum (Vaselinum hydrophylicum), lanolin (Lanolinum), cold cream (Unguentum leniens); ointment bases washable with water, such as hydrophilic ointment (Unguentum hydrophylum); water-soluble ointment bases, such as polyethylene glycol ointment (Unguentum Glycolis Polyaethyleni), bentonite bases and others.
- absorbent ointment bases such as hydrophilic petrolatum (Vaselinum hydrophylicum), lanolin (Lanolinum), cold cream (Un
- methyl cellulose sodium carboxymethyl cellulose, hydroxypropyl cellulose, polyethylene glycol or polyethylene oxide, carbopol can be used.
- the amount of active ingredient used in combination with a carrier may vary depending on the recipient being treated, on the particular route of administration of the drug.
- the content of the active agent in them is up to 5% by weight.
- diluents 0.9% sodium chloride solution, distilled water, novocaine solution for injection, Ringer's solution, glucose solution, specific additives for dissolution can be used.
- their amount is up to 200 mg per unit dosage form.
- Dosage forms of the present invention are obtained according to standard methods, such as, for example, mixing, granulating, dragee formation, dissolution and lyophilization.
- the compounds of the present invention exhibit biological activity in doses two to three orders of magnitude lower compared with the known drugs used for comparison, with almost the same effectiveness, and for them there were no negative side effects and no contraindications for use.
- Chromatograms and electrophoregrams exhibit chlorotetramethylbenzidine reagent and Pauli reagent.
- HPLC SCLlOAvp PE SCIEX API 165 (150) mass spectrometer, (Canada), and LC MS analysis system for multicomponent mixtures.
- Analytical reverse-phase HPLC was performed on an instrument: Shimadzu HPLC chromatograph under conditions: Symmetry C18 column 250x4.6 mm, elution gradient in water system with 0.1% HCOOH: acetonitrile with 0.1% HCOOH (conditions A); column Merk.LiChroCART 250x4mm 5mkm. LiChrospher 100RP-8E 5 mkm.C8.
- the mother liquor after filtration is extracted three times with methylene chloride.
- the combined organic mother liquors are dried with sodium sulfate, the solvent is removed in vacuo.
- the precipitate formed is dried, combined with the first portion (after filtration), and 0.52 g is obtained with a yield of 56% of 1- (2- (1H-imidazol-4-yl) ethyl) piperidine-2,6-dione, as a light powder.
- the resulting solution was concentrated in vacuo, distilling off about 70% of methylene chloride, and left for 18 hours at a temperature of 0 - + 4 ° C.
- the precipitate is filtered off, washed with three portions of isopropanol, cooled to 0 - -5 ° C.
- the technical product is recrystallized, while the hot solution of the product is treated with coal dust / coal.
- the purity of the product is monitored by TLC (Rf of product 0.54 (1)).
- the product solution is hot filtered on the MILLIPORE filtration system (0.45 ⁇ m), dried in a vacuum oven at + 70 ° C.
- the induction of acute rhinosinusitis was carried out by intranasal administration to rats of 20 ⁇ l of 7.5% formalin (an aqueous solution containing 40% formaldehyde, 8% methyl alcohol and 52% water) in each nasal passage.
- a clinical examination of each animal was carried out daily at least 2 times a day.
- HCXV A2 pre-adapted and causing the death of mice from coxsaki virus infection.
- the ability of the compounds to exert a therapeutic effect was judged by the death of mice infected with the HCXV A2 virus in the experimental group compared with the group of animals not receiving treatment.
- mice were injected with saline as a placebo.
- Negative controls were intact animals that were kept under the same conditions as the experimental groups in a separate room.
- mice For the experiment, groups of 14-15 mice each were formed. Compounds were administered at a dose of 30 mg / kg body weight. The test substances were administered orally, 1 time per day, for 7 days (the first administration - 24 hours after infection). Observation of animals was carried out for 15 days, daily weighing and recording the mortality of animals.
- mice To determine the antiviral efficacy of chemical compounds against RSV in an in vivo experimental mouse model, the human hRSV virus, previously adapted for growth in the lungs of mice, was used. ' Animals were infected with the virus at a dose of 5.0 logTCID 0 intranasally under mild ether anesthesia in a volume of 0.05 ml / mouse. The studied compounds were administered to animals orally 1 time per day for 5 days according to the treatment regimen at a dose of 30 mg / kg. The first administration was carried out 24 hours after infection. Mice were injected with saline as a placebo. Negative controls were intact animals that were kept in a separate room under the same conditions as the experimental groups. The experimental groups contained 12 mice. Ribavirin at a dose of 40 mg / kg served as a comparison drug.
- Evaluation of the antiviral activity of the test compound was carried out according to the effectiveness of preventing weight loss and suppressing the reproduction of hRSV in the lungs of infected mice by measuring the viral titer in the experimental groups compared to the control on the 5th and 7th days after infection.
- mice The average body weight of mice on the 5th and 7th day after
- the therapeutic effect of the compounds of general formula I evaluated by their ability to suppress the reproduction of hRSV virus in the lungs of mice 5 and 7 days after infection.
- the virus titer was determined by titration of a 10% suspension of the lungs on a culture of Hep-2 cells. The result was taken into account after 2 days of incubation at 37 ° C according to the CPD.
- the results of determining the infectious activity of hRSV in mouse lung suspensions in a Hep-2 cell culture after application of the test compounds and the comparative preparation are presented in Table 8.
- the antiviral activity of chemical compounds against human respiratory syncytial virus was evaluated on a model of viral pneumonia in Balb / c mice.
- the virus was administered intranasally to animals in a volume of 50 ⁇ l under light ether anesthesia.
- the animals were injected intraperitoneally with cyclophosphamide at a dose of 100 mg / kg.
- the studied compounds were used according to the treatment regimen once a day at a dose of 30 mg / kg for 5 days, starting 24 hours after infection.
- the activity of the compounds was evaluated by reducing the edema of an infected respiratory syncytial lung virus compared with the control on the fifth day after infection.
- Ribavirin 50 1.00 ⁇ 0.17 *
- the virus was pre-titrated in mice, then the mice were infected and the drug was orally administered. On the 2nd, 3rd and 4th day after infection, the infectious titer of the virus was evaluated by titration of a pulmonary suspension in a Hela cell culture.
- the tested compounds and placebo were administered to animals orally 1 time per day, for 5 days, starting after 12 hours after infection.
- the drug was administered at a dose of 30 mg / kg of animal body weight.
- As a negative control intact animals were used in an amount of 10, which were kept in a separate room under the same conditions as the experimental groups.
- the antiviral activity of the test compounds was evaluated by the dynamics of changes in body weight and lungs of mice and by the reduction of the infectious activity of the virus, as determined in the Hela cell culture.
- the infectious titer of RV virus in the lungs of animals of the experimental group compared to the group of animals that did not receive treatment was determined by the CPD.
- mice after hRV infection Light weight of mice after hRV infection
- each animal was examined daily.
- the examination included an assessment of the general behavior and condition of the animals.
- On the days of drug administration the examination was carried out before the drug was administered at the prescribed time and approximately 2 hours after the administration.
- the handling of animals was carried out in accordance with international standards.
- mice were given a placebo (0.2 ml of physiological saline) under the same conditions. The animals were observed for 14 days. after infection, given the death of mice from influenza pneumonia in groups of treated animals and in the control. The specificity of the death of animals from influenza pneumonia was confirmed by the registration of pathological changes in the lungs of fallen animals.
- the activity of the compounds was evaluated by comparing mortality in groups of animals that took the drug and placebo.
- the life expectancy of infected animals taking a placebo was 7.2 ⁇ 2.2 days. with a mortality rate of 95%.
- the compounds of the invention may be administered orally, intramuscularly or intravenously in unit dosage form containing non-toxic pharmaceutically acceptable carriers.
- These compounds may be administered to a patient in doses ranging from 0.1 to 10 mg / kg of body weight per day, preferably in doses of 0.5 to 5 mg / kg, one or more times per day.
- the specific dose for each particular patient will depend on many factors, including age, body weight, gender, general health status and diet of the patient, time and method of administering the drug, its rate of elimination from the body, and severity disease in this patient undergoing treatment.
- compositions contain the compounds of the invention in an amount effective to achieve a positive result, and can be administered in unit dosage forms (e.g., in solid, semi-solid or liquid forms) containing the compound as an active ingredient in admixture with a carrier or excipient, suitable for oral, intramuscular or intravenous administration.
- a carrier or excipient suitable for oral, intramuscular or intravenous administration.
- the active ingredient may be included in the composition along with commonly used non-toxic pharmaceutically acceptable carriers suitable for the manufacture of solutions, tablets, pills, capsules, dragees and any other dosage forms.
- binders can be used such as starch paste, for example, corn, wheat, rice, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl methyl cellulose, sodium carboxymethyl cellulose and / or polyvinylpyrrolidone.
- disintegrating agents such as the aforementioned starches and carboxymethyl starch, crosslinked polyvinylpyrrolidone, agar or alginic acid or a salt thereof, such as sodium alginate, can be used.
- Optional additives may also be included, for example, flow control agents and lubricants, such as silica, talc, stearic acid and its salts, such as magnesium stearate or calcium stearate, and / or propylene glycol.
- flow control agents and lubricants such as silica, talc, stearic acid and its salts, such as magnesium stearate or calcium stearate, and / or propylene glycol.
- stabilizers, thickeners, colorants and perfumes can also be used.
- the amount of active ingredient used in combination with a carrier may vary depending on the patient being treated and on the particular method of drug administration.
- the content of the active agent in them is 0.01-5 wt.%.
- diluents 0.9% sodium chloride solution, distilled water, novocaine solution for injection, Ringer's solution, glucose solution, specific additives for dissolution can be used.
- their amount is 5.0-500 mg per standard dosage form.
- Dosage forms of the compounds of the invention for use in accordance with the present invention are prepared according to standard procedures, such as, for example, mixing, granulation, dragee formation, dissolution and lyophilization.
- a tablet form is prepared using the following ingredients:
- the components are mixed and compressed to form tablets.
- the compound of the invention or its pharmaceutically 1 -100 mg
- composition of the solution for injection is an example of the composition of the solution for injection:
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
Claims
Priority Applications (38)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14782170.6A EP2985282A4 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
AU2014251442A AU2014251442A1 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
EP20178488.1A EP3725785B1 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative |
IL266301A IL266301B2 (en) | 2013-04-12 | 2014-04-10 | History of glutarimide, their use, pharmaceutical preparation based on them and methods for producing history of glutarimide |
SG11201508394UA SG11201508394UA (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
KR1020207016274A KR102296182B1 (ko) | 2013-04-12 | 2014-04-10 | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 |
CN201480032755.8A CN106061962B (zh) | 2013-04-12 | 2014-04-10 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
MX2020005735A MX2020005735A (es) | 2013-04-12 | 2014-04-10 | Derivados de glutarimida, uso de los mismos, composición farmacéutica basada en los mismos y métodos para producir derivados de glutarimida. |
KR1020207016268A KR102254315B1 (ko) | 2013-04-12 | 2014-04-10 | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 |
EA201591957A EA031392B1 (ru) | 2013-04-12 | 2014-04-10 | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |
MX2020005736A MX2020005736A (es) | 2013-04-12 | 2014-04-10 | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
BR122020010204-7A BR122020010204B1 (pt) | 2013-04-12 | 2014-04-10 | Composto derivado de glutarimida, seu uso, composiçâo farmacêutica e método de de preparação |
JP2016507512A JP6529958B2 (ja) | 2013-04-12 | 2014-04-10 | グルタルイミド誘導体、その使用、それに基づいた医薬組成物及びグルタルイミド誘導体を製造するための方法 |
BR112015025804-2A BR112015025804B1 (pt) | 2013-04-12 | 2014-04-10 | Derivados de glutarimida, uso dos mesmos, composição farmacêutica com base neles e métodos para a produção de derivados de glutarimida |
BR122020010210-1A BR122020010210B1 (pt) | 2013-04-12 | 2014-04-10 | Composto derivado de glutarimida, seu uso, composição farmacêutica e método de preparação do mesmo |
MX2015014336A MX2015014336A (es) | 2013-04-12 | 2014-04-10 | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
CA2909057A CA2909057C (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
EP20178489.9A EP3722290B1 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivative, use thereof, pharmaceutical composition based thereon and methods for producing the glutarimide derivative |
KR1020157032457A KR102255929B1 (ko) | 2013-04-12 | 2014-04-10 | 글루타르이미드 유도체, 이의 용도, 이를 기반으로 한 약학 조성물 및 글루타르이미드 유도체를 생산하는 방법 |
UAA201511008A UA121299C2 (uk) | 2013-04-12 | 2014-04-10 | Похідні глутарімідів, їх застосування, фармацевтична композиція на їх основі, способи їх одержання |
CN201910437241.5A CN110229140B (zh) | 2013-04-12 | 2014-04-10 | 戊二酰亚胺衍生物、其用途、基于所述衍生物的药物组合物及戊二酰亚胺衍生物的制备方法 |
US14/783,911 US9815814B2 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
MX2020005738A MX2020005738A (es) | 2013-04-12 | 2014-04-10 | Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida. |
IL241998A IL241998B (en) | 2013-04-12 | 2015-10-11 | History of glutarimide, their use, pharmaceutical preparation based on them and methods for producing history of glutarimide |
ZA2015/08278A ZA201508278B (en) | 2013-04-12 | 2015-11-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,274 US10196377B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,252 US10155745B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,207 US10155743B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,316 US10155747B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,295 US10155746B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,226 US10155744B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
AU2018236805A AU2018236805C1 (en) | 2013-04-12 | 2018-09-27 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US16/192,065 US10377739B2 (en) | 2013-04-12 | 2018-11-15 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
IL266300A IL266300B (en) | 2013-04-12 | 2019-04-29 | Antecedents of glutarimide, their use, a pharmaceutical preparation based on them and methods for producing antecedents of glutarimide |
IL266302A IL266302B (en) | 2013-04-12 | 2019-04-29 | History of glutarimide, their use, pharmaceutical preparation based on them and methods for producing history of glutarimide |
AU2020203630A AU2020203630B2 (en) | 2013-04-12 | 2020-06-02 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
AU2020203632A AU2020203632B2 (en) | 2013-04-12 | 2020-06-02 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
AU2020203968A AU2020203968B2 (en) | 2013-04-12 | 2020-06-15 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2013116826 | 2013-04-12 | ||
RU2013116826A RU2562773C3 (ru) | 2013-04-12 | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |
Related Child Applications (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/783,911 A-371-Of-International US9815814B2 (en) | 2013-04-12 | 2014-04-10 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,252 Continuation US10155745B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,207 Continuation US10155743B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,295 Continuation US10155746B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,226 Continuation US10155744B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,274 Continuation US10196377B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
US15/718,316 Division US10155747B2 (en) | 2013-04-12 | 2017-09-28 | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2014168522A1 WO2014168522A1 (ru) | 2014-10-16 |
WO2014168522A9 true WO2014168522A9 (ru) | 2014-12-04 |
WO2014168522A4 WO2014168522A4 (ru) | 2015-01-22 |
Family
ID=51689819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/RU2014/000264 WO2014168522A1 (ru) | 2013-04-12 | 2014-04-10 | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |
Country Status (15)
Country | Link |
---|---|
US (8) | US9815814B2 (ru) |
EP (3) | EP2985282A4 (ru) |
JP (4) | JP6529958B2 (ru) |
KR (3) | KR102296182B1 (ru) |
CN (4) | CN110128406B (ru) |
AU (5) | AU2014251442A1 (ru) |
BR (3) | BR122020010210B1 (ru) |
CA (1) | CA2909057C (ru) |
EA (4) | EA031392B1 (ru) |
IL (4) | IL266301B2 (ru) |
MX (4) | MX2020005738A (ru) |
SG (4) | SG10201802650WA (ru) |
UA (1) | UA121299C2 (ru) |
WO (1) | WO2014168522A1 (ru) |
ZA (3) | ZA201508278B (ru) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11439631B2 (en) | 2017-09-07 | 2022-09-13 | “ChemImmune Therapeutics” Limited Liability Company | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9815814B2 (en) * | 2013-04-12 | 2017-11-14 | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
RU2552929C1 (ru) | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | 王晓旭 | 一种治疗高血脂症的药物 |
EP3873890A4 (en) * | 2018-11-01 | 2022-09-07 | Ahammune Biosciences Private Limited | NEW IMIDAZOLE COMPOUNDS, PROCESS FOR SYNTHESIS AND ASSOCIATED USES |
RU2712281C1 (ru) | 2018-11-23 | 2020-01-28 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
BR112022026356A2 (pt) * | 2020-06-26 | 2023-01-17 | Valenta Intellekt Ltd | Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 |
WO2023121519A1 (ru) * | 2021-12-23 | 2023-06-29 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Применение 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-диона для лечения covid-19 |
WO2023177329A1 (ru) * | 2022-03-18 | 2023-09-21 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Применение 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона для лечения кашля, вызванного вирусными инфекциями |
WO2023191666A1 (ru) * | 2022-03-29 | 2023-10-05 | Общество С Ограниченной Ответственностью "Валента-Интеллект" | Кристаллическая форма 1-(2-(1н-имидазол-4-ил)этил)пиперидин-2,6-диона и ее применение |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3081308A (en) * | 1959-12-29 | 1963-03-12 | Searle & Co | 5-carbocyclic-3-imidomethyloxazolidines and process |
US3171839A (en) * | 1961-05-18 | 1965-03-02 | Searle & Co | 4-alkyl-1-(cyclic imidoalkyl) piperidines |
GB1033251A (en) * | 1961-09-07 | 1966-06-22 | Distillers Co Yeast Ltd | Glutarimide derivatives |
US3963691A (en) * | 1974-10-07 | 1976-06-15 | Merck & Co., Inc. | Synthetic antigens of luteinizing hormone releasing hormone |
US4261990A (en) * | 1979-03-09 | 1981-04-14 | Ciba-Geigy Corporation | N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics |
JPS606686A (ja) * | 1983-06-27 | 1985-01-14 | Kissei Pharmaceut Co Ltd | チオフエン誘導体及びその製造方法 |
JPS6066686A (ja) | 1983-09-19 | 1985-04-16 | Toshiba Corp | ライン駆動電動機の速度制御装置 |
SE8600261D0 (sv) * | 1986-01-21 | 1986-01-21 | Lundblad Leif | Indolokinoxaliner med substituenter i 6-position som innehaller cykliska grupper |
SU1836365A3 (ru) * | 1991-01-24 | 1993-08-23 | Физиko-Xиmичeckий Иhctиtуt Иm.A.B.Бoгatckoгo;Hии@ Фapmakoлoгии Poccийckoй Amh | Способ получения ν-0-пиперазинил)бутилглутаримидов |
FR2737725B1 (fr) | 1995-08-08 | 1997-10-31 | Valentonine | Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament |
RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
AU8998598A (en) * | 1997-09-11 | 1999-03-29 | Nissan Chemical Industries Ltd. | Pyrazole compounds and plant disease control agent |
ITMI991578A1 (it) | 1999-07-15 | 2001-01-15 | Recordati Ind Chimica E Farma | Amidi e imidi cicliche dotate di attivita' antagonista selettiva per il recettore adrenergico |
US6413428B1 (en) | 1999-09-16 | 2002-07-02 | Berger Instruments, Inc. | Apparatus and method for preparative supercritical fluid chromatography |
DE10002509A1 (de) * | 2000-01-21 | 2001-07-26 | Gruenenthal Gmbh | Substituierte Glutarimide |
US7030150B2 (en) * | 2001-05-11 | 2006-04-18 | Trimeris, Inc. | Benzimidazole compounds and antiviral uses thereof |
AU2003263393A1 (en) * | 2002-09-04 | 2004-03-29 | Glenmark Pharmaceuticals Limited | New heterocyclic amide compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them |
MXPA05013224A (es) | 2003-06-12 | 2006-03-09 | Novo Nordisk As | Piridinilcarbamatos como inhibidores de lipasa sensible a hormonas. |
CN1260218C (zh) * | 2003-11-06 | 2006-06-21 | 天津药物研究院 | 一类pdf酶抑制剂-异羟肟酸系列化合物及其合成方法与用途 |
WO2006040646A1 (en) * | 2004-10-14 | 2006-04-20 | Pfizer, Inc. | Benzimidazole or indole amides as inhibitors of pin1 |
KR100917511B1 (ko) * | 2005-02-28 | 2009-09-16 | 니뽄 다바코 산교 가부시키가이샤 | Syk 저해 활성을 갖는 신규한 아미노피리딘 화합물 |
EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
WO2007007054A1 (en) * | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
US20120157387A1 (en) * | 2006-11-28 | 2012-06-21 | Apotex Technologies Inc. | Orally bioavailable d-gamma-glutamyl-d-tryptophan |
US8557836B2 (en) * | 2008-09-16 | 2013-10-15 | The Trustees Of The University Of Pennsylvania | Spiro-piperidine inhibitors |
ES2647223T3 (es) * | 2010-04-15 | 2017-12-20 | Biota Scientific Management Pty Ltd | Vapendavir para el alivio de los síntomas del asma en un sujeto que tiene una infección por el VRH |
TW201217312A (en) * | 2010-09-22 | 2012-05-01 | Gruenenthal Gmbh | Substituted benzamide compounds |
US20120157382A1 (en) * | 2010-12-21 | 2012-06-21 | Siegfried Krimmer | Pharmaceutical glp-1 compositions having an improved release profile |
US9815814B2 (en) | 2013-04-12 | 2017-11-14 | Obschestvo S Ogranichennoi Otvetstvennostiyu “Pharmenterprises” | Glutarimide derivatives, use thereof, pharmaceutical composition based thereon and methods for producing glutarimide derivatives |
RU2665688C2 (ru) * | 2013-04-12 | 2018-09-04 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Производные бисамидов дикарбоновых кислот, их применение, фармацевтическая композиция на их основе, способы их получения |
RU2552929C1 (ru) * | 2013-11-14 | 2015-06-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
-
2014
- 2014-04-10 US US14/783,911 patent/US9815814B2/en active Active
- 2014-04-10 EA EA201591957A patent/EA031392B1/ru unknown
- 2014-04-10 CN CN201910437242.XA patent/CN110128406B/zh active Active
- 2014-04-10 BR BR122020010210-1A patent/BR122020010210B1/pt not_active IP Right Cessation
- 2014-04-10 SG SG10201802650WA patent/SG10201802650WA/en unknown
- 2014-04-10 MX MX2020005738A patent/MX2020005738A/es unknown
- 2014-04-10 MX MX2020005736A patent/MX2020005736A/es unknown
- 2014-04-10 SG SG10201802647QA patent/SG10201802647QA/en unknown
- 2014-04-10 CN CN201910437241.5A patent/CN110229140B/zh active Active
- 2014-04-10 EP EP14782170.6A patent/EP2985282A4/en not_active Withdrawn
- 2014-04-10 KR KR1020207016274A patent/KR102296182B1/ko active IP Right Grant
- 2014-04-10 IL IL266301A patent/IL266301B2/en unknown
- 2014-04-10 SG SG10201802648SA patent/SG10201802648SA/en unknown
- 2014-04-10 EA EA201792072A patent/EA032951B1/ru unknown
- 2014-04-10 JP JP2016507512A patent/JP6529958B2/ja active Active
- 2014-04-10 BR BR112015025804-2A patent/BR112015025804B1/pt not_active IP Right Cessation
- 2014-04-10 EA EA201792071A patent/EA033054B1/ru unknown
- 2014-04-10 SG SG11201508394UA patent/SG11201508394UA/en unknown
- 2014-04-10 BR BR122020010204-7A patent/BR122020010204B1/pt active IP Right Grant
- 2014-04-10 UA UAA201511008A patent/UA121299C2/uk unknown
- 2014-04-10 CN CN201480032755.8A patent/CN106061962B/zh not_active Expired - Fee Related
- 2014-04-10 WO PCT/RU2014/000264 patent/WO2014168522A1/ru active Application Filing
- 2014-04-10 KR KR1020207016268A patent/KR102254315B1/ko active IP Right Grant
- 2014-04-10 CN CN201910437243.4A patent/CN110172055B/zh active Active
- 2014-04-10 AU AU2014251442A patent/AU2014251442A1/en not_active Abandoned
- 2014-04-10 MX MX2020005735A patent/MX2020005735A/es unknown
- 2014-04-10 EA EA201792597A patent/EA032938B1/ru not_active IP Right Cessation
- 2014-04-10 EP EP20178489.9A patent/EP3722290B1/en active Active
- 2014-04-10 CA CA2909057A patent/CA2909057C/en active Active
- 2014-04-10 MX MX2015014336A patent/MX2015014336A/es unknown
- 2014-04-10 KR KR1020157032457A patent/KR102255929B1/ko active IP Right Grant
- 2014-04-10 EP EP20178488.1A patent/EP3725785B1/en active Active
-
2015
- 2015-10-11 IL IL241998A patent/IL241998B/en active IP Right Grant
- 2015-11-10 ZA ZA2015/08278A patent/ZA201508278B/en unknown
-
2016
- 2016-05-10 ZA ZA2016/03109A patent/ZA201603109B/en unknown
- 2016-05-10 ZA ZA2016/03108A patent/ZA201603108B/en unknown
-
2017
- 2017-09-28 US US15/718,252 patent/US10155745B2/en active Active
- 2017-09-28 US US15/718,226 patent/US10155744B2/en active Active
- 2017-09-28 US US15/718,274 patent/US10196377B2/en active Active
- 2017-09-28 US US15/718,316 patent/US10155747B2/en active Active
- 2017-09-28 US US15/718,295 patent/US10155746B2/en active Active
- 2017-09-28 US US15/718,207 patent/US10155743B2/en active Active
-
2018
- 2018-09-27 AU AU2018236805A patent/AU2018236805C1/en not_active Ceased
- 2018-11-07 JP JP2018209574A patent/JP6620324B2/ja active Active
- 2018-11-07 JP JP2018209573A patent/JP6627039B2/ja active Active
- 2018-11-07 JP JP2018209575A patent/JP6843103B2/ja active Active
- 2018-11-15 US US16/192,065 patent/US10377739B2/en active Active
-
2019
- 2019-04-29 IL IL266300A patent/IL266300B/en unknown
- 2019-04-29 IL IL266302A patent/IL266302B/en unknown
-
2020
- 2020-06-02 AU AU2020203632A patent/AU2020203632B2/en active Active
- 2020-06-02 AU AU2020203630A patent/AU2020203630B2/en active Active
- 2020-06-15 AU AU2020203968A patent/AU2020203968B2/en not_active Ceased
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11439631B2 (en) | 2017-09-07 | 2022-09-13 | “ChemImmune Therapeutics” Limited Liability Company | Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2014168522A9 (ru) | Производные глутаримидов, их применение, фармацевтическая композиция на их основе, способы их получения |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14782170 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2909057 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2016507512 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2015/014336 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 241998 Country of ref document: IL |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14783911 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201511008 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201591957 Country of ref document: EA Ref document number: IDP00201507278 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 20157032457 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014782170 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014251442 Country of ref document: AU Date of ref document: 20140410 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112015025804 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112015025804 Country of ref document: BR Kind code of ref document: A2 Effective date: 20151009 |